Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc - 1 Jul 2022

Ross Dara S, Devereaux Kelly A, Jin Cao, Lin David YunTe, Zhang Yanming, Marra Antonio, Makker Vicky, Weigelt Britta, Ellenson Lora H, Chui M Herman

Abstract excerpt

HER2 is an established therapeutic biomarker in advanced or recurrent endometrial serous carcinoma. Current clinical guidelines recommend HER2 testing exclusively in this endometrial carcinoma (EC) subtype; however, the full spectrum of ECs harboring HER2 amplification remains ill-defined. The present study characterizes the clinicopathologic and molecular features of HER2-amplified ECs across all histologic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinosarcoma
Share to Cystadenocarcinoma, Serous

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endometrial Neoplasms

Share to Molecular Biology

Share to Mutation

Share to Neoplasm Recurrence, Local

Source

Open in PubMed Open full text

Identifiers

PMID: 34972830
DOI: 10.1038/s41379-021-00997-2
PMCID: PMC9990080

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas.PMID 34972830Read ↗

ERBB2 mutations define a subgroup of endometrial carcinomas associated with high tumor mutational burden and the microsatellite instability-high (MSI-H) molecular subtype.Semantic proximity Read ↗

HER2+ endometrioid endometrial cancer possesses distinct molecular and immunologic features associated with a more active immune microenvironment and worse prognosis.Semantic proximity Read ↗

Distinct molecular landscapes between endometrioid and nonendometrioid uterine carcinomasSemantic proximity Read ↗

ERBB2 amplification is a late event in the pathogenesis of high-grade endometrial carcinomas with heterogeneous HER2 expression.Semantic proximity Read ↗

Clinicopathologic and Genomic Analysis of TP53-Mutated Endometrial Carcinomas.Semantic proximity Read ↗

Molecular Characterization and Clinical Implications of Endometrial Cancer.Semantic proximity Read ↗

Molecular Genetics of Endometrial CarcinomaSemantic proximity Read ↗

Molecular Classification of Endometrial Carcinomas: Review and Recent UpdatesSemantic proximity Read ↗

High-grade endometrial carcinomas: Morphologic spectrum and molecular classification.Semantic proximity Read ↗

Comprehensive Review of Endometrial Cancer: New Molecular and FIGO Classification and Recent Treatment ChangesSemantic proximity Read ↗

Molecular landscape of ERBB2/HER2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions.Semantic proximity Read ↗

Clinical Application of Next-Generation Sequencing for Molecular Classification in the Management of Endometrial Cancer: An Observational Cohort StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.